Cannes Lions Health postpones June advertising festival, looks to reschedule in October

Flags flying outside Cannes Lions 2019
Cannes Lions Health is officially postponed as organizers plan to move the annual event from June to October. (Beth Snyder Bulik)

Cannes Lions Health has officially moved its annual June conference and awards to October. The decision to postpone the entire Cannes Lions advertising festival comes amid many global event postponements and cancellations due to the COVID-19 pandemic.

The tentative new dates for the Lions in Cannes, France, are Oct. 26-30. Cannes organizers sent an email to attendees just one week ago to flag the possibility of a move and promised a definitive answer by mid-April.

RELATED: AACR joins list of medical conferences to get axed, postponed amid coronavirus spread


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

Cannes organizers noted the decision was made in consultation with public health officials as well as local Cannes and French authorities. The event, begun in the 1950s, draws more than 10,000 people from ad agencies and brand marketers from 90 countries around the world to the south of France for a week. Lions Health, the pharma and healthcare track established in 2014, runs for the first two days of the event.

“Our community is facing unprecedented challenges and collaboration has never been more important. We are focused now on planning the festival—and our beating heart, the Lions—to ensure our community is able to recognise the extraordinary work it contributes to business, organizations and society,” Simon Cook, managing director of Cannes Lions, said in a news release.

Suggested Articles

Johnson & Johnson has expanded its COVID-19 vaccine production pact with CDMO Catalent to include work at the manufacturer's Anagni, Italy site.

German vaccine maker CureVac scored an $85 million EU loan to expand manufacturing for its mRNA-based COVID-19 vaccine hopeful.

Learn how drug substance and drug product early development strategies are important for optimization and long-term success.